title: Operator independent left ventricular function monitoring during pharmacological stress echo with the new peak transcutaneous acceleration signal.
abstract: BACKGROUND
  As the myocardium contracts isometrically, it generates vibrations that can be measured with an accelerometer. The vibration peak, peak endocardial acceleration (PEA), is an index of contractility.
  
  
  OBJECTIVE
  To evaluate the feasibility of PEA measured by the cutaneous precordial application of the accelerometer sensor; and to assess the usefulness of PEA monitoring during pharmacological stress echocardiography.
  
  
  METHODS
  Feasibility study.
  
  
  METHODS
  Stress echo laboratory.
  
  
  METHODS
  34 consecutive patients underwent pharmacological stress (26 with dipyridamole; 8 with dobutamine) and PEA monitoring simultaneously.
  
  
  METHODS
  A microaccelerometer was positioned in the precordial region and PEA was recorded. Dipyridamole was infused up to 0.84 mg/kg in 10 minutes, and dobutamine up to 40 microg/kg/min in 15 minutes.
  
  
  RESULTS
  A consistent PEA signal was obtained in all patients. Overall mean (SD) baseline PEA was 0.26 (0.15) g (g = 9.8 m/s(2)), increasing to 0.5 (0.36) g at peak stress (+0.24 g, 95% confidence interval (CI) 0.14 to 0.34 g; p < 0.01). PEA increased from 0.26 (0.16) to 0.37 (0.25) g in the dipyridamole group (+0.11 g, 95% CI 0.08 to 0.16 g; p < 0.01), and from 0.29 (0.1) to 0.93 (0.37) g in the dobutamine group (+0.64 g, 95% CI 0.37 to 0.91 g; p < 0.01).
  
  
  CONCLUSIONS
  Using precordial leads this method offers potential for diagnostic application in the short term monitoring of myocardial function. PEA monitoring is feasible during pharmacological stress and documents left ventricular inotropic response quantitatively in a non-invasive and operator independent fashion.
authors.affiliation: Biomedical Technology Department, Bologna University, Bologna, Italy. tecbio@med.unibo.it
authors.forename: T
authors.initials: T
authors.lastname: Bombardini
authors.forename: E
authors.initials: E
authors.lastname: Marcelli
authors.forename: E
authors.initials: E
authors.lastname: Picano
authors.forename: B
authors.initials: B
authors.lastname: Borghi
authors.forename: P
authors.initials: P
authors.lastname: Fedriga
authors.forename: B
authors.initials: B
authors.lastname: Garberoglio
authors.forename: G
authors.initials: G
authors.lastname: Gaggini
authors.forename: G
authors.initials: G
authors.lastname: Plicchi
mesh_terms: D000054:Acceleration; D002317:Cardiovascular Agents; D004176:Dipyridamole; D004280:Dobutamine; D004452:Echocardiography / Q000379:methods; D004562:Electrocardiography; D005080:Exercise Test; D005240:Feasibility Studies; D006352:Heart Ventricles / Q000000981:diagnostic imaging*; D006801:Humans; D008991:Monitoring, Physiologic / Q000295:instrumentation / Q000379:methods*; D009200:Myocardial Contraction; D016276:Ventricular Function; D016277:Ventricular Function, Left
chemical_list: D002317:Cardiovascular Agents; D004280:Dobutamine; D004176:Dipyridamole